KRASG12C inhibition produces a driver-limited state revealing collateral dependencies
出版年份 2019 全文链接
标题
KRASG12C inhibition produces a driver-limited state revealing collateral dependencies
作者
关键词
-
出版物
Science Signaling
Volume 12, Issue 583, Pages eaaw9450
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2019-05-29
DOI
10.1126/scisignal.aaw9450
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
- (2018) Matthew R. Janes et al. CELL
- Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS G12C-Driven Mouse Model of Lung Cancer
- (2018) Shuai Li et al. CLINICAL CANCER RESEARCH
- KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
- (2018) Marta Román et al. Molecular Cancer
- Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
- (2018) Dietrich A. Ruess et al. NATURE MEDICINE
- SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
- (2018) Sara Mainardi et al. NATURE MEDICINE
- Afatinib restrains K-RAS–driven lung tumorigenesis
- (2018) Herwig P. Moll et al. Science Translational Medicine
- The ERBB network facilitates KRAS-driven lung tumorigenesis
- (2018) Björn Kruspig et al. Science Translational Medicine
- RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
- (2018) Robert J. Nichols et al. NATURE CELL BIOLOGY
- KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
- (2018) Sandra Misale et al. CLINICAL CANCER RESEARCH
- Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
- (2017) Collin M Blakely et al. NATURE GENETICS
- Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells
- (2017) Robin M Meyers et al. NATURE GENETICS
- PICKLES: the database of pooled in-vitro CRISPR knockout library essentiality screens
- (2017) Walter F Lenoir et al. NUCLEIC ACIDS RESEARCH
- An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer
- (2017) Adrian Vallejo et al. Nature Communications
- Synthetic Lethal Vulnerabilities in KRAS -Mutant Cancers
- (2017) Andrew J. Aguirre et al. Cold Spring Harbor Perspectives in Medicine
- BAGEL: a computational framework for identifying essential genes from pooled library screens
- (2016) Traver Hart et al. BMC BIOINFORMATICS
- Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation
- (2016) Christopher J. Tape et al. CELL
- XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer
- (2016) Jimi Kim et al. NATURE
- Overcoming resistance to HER2 inhibitors through state-specific kinase binding
- (2016) Chris J Novotny et al. Nature Chemical Biology
- Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
- (2016) P. Lito et al. SCIENCE
- Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
- (2016) M. P. Patricelli et al. Cancer Discovery
- Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation
- (2016) Max A Horlbeck et al. eLife
- Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions
- (2015) S. Fujita-Sato et al. CANCER RESEARCH
- RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
- (2015) J. Downward CLINICAL CANCER RESEARCH
- MSstats: an R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments
- (2014) Meena Choi et al. BIOINFORMATICS
- Oncogenic KRAS signalling in pancreatic cancer
- (2014) S Eser et al. BRITISH JOURNAL OF CANCER
- The RhoGEF GEF-H1 Is Required for Oncogenic RAS Signaling via KSR-1
- (2014) Jane Cullis et al. CANCER CELL
- Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation
- (2014) Luke A. Gilbert et al. CELL
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- RegPhos 2.0: an updated resource to explore protein kinase–substrate phosphorylation networks in mammals
- (2014) Kai-Yao Huang et al. Database-The Journal of Biological Databases and Curation
- PhosphoNetworks: a database for human phosphorylation networks
- (2013) J. Hu et al. BIOINFORMATICS
- Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer
- (2013) Hyun Seok Kim et al. CELL
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- RNAi screens in mice identify physiological regulators of oncogenic growth
- (2013) Slobodan Beronja et al. NATURE
- mTORC1 Status Dictates Tumor Response to Targeted Therapeutics
- (2013) I. Kelsey et al. Science Signaling
- Systematic Functional Prioritization of Protein Posttranslational Modifications
- (2012) Pedro Beltrao et al. CELL
- Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks
- (2012) Michael J. Lee et al. CELL
- Identification of Mutant K-Ras-dependent Phenotypes Using a Panel of Isogenic Cell Lines
- (2012) Steffan Vartanian et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
- (2012) Levi A. Garraway et al. Cancer Discovery
- Knockdown of Oncogenic KRAS in Non-Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
- (2011) N. Sunaga et al. MOLECULAR CANCER THERAPEUTICS
- A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
- (2010) Marta Puyol et al. CANCER CELL
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- A mammalian functional-genetic approach to characterizing cancer therapeutics
- (2010) Hai Jiang et al. Nature Chemical Biology
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
- (2009) Ji Luo et al. CELL
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
- (2009) Da Wei Huang et al. Nature Protocols
- Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
- (2008) K. S.M. Smalley et al. MOLECULAR CANCER THERAPEUTICS
- MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification
- (2008) Jürgen Cox et al. NATURE BIOTECHNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now